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Multiple epigenetic changes, including alterations in DNA methylation occur during tumorigenesis. Various
inhibitors of DNA methylation have been developed to prevent proliferation of cancer cells. 5-fluoro-20-
deoxycytidine (FCdR) is one such DNA methylation inhibitor, which is currently in phase II clinical trial. To
investigate the molecular mechanism/s by which FCdR might mediate repression of tumor cell proliferation, we
analyzed the toxicity of FCdR in various cell lines established from different sarcomas. We found HCT116, a colon
cancer cell line, is much more sensitive to FCdR compared to others. FCdR treatment inhibited HCT116 cells at G2/
M check point and up-regulated expression of multiple cancer-related genes, which could be due to its inhibitory
activity towards DNA methylation. Furthermore, we found that FCdR activates DNA damage response pathway.
Using an inhibitor for ATM and ATR kinases activity, which are required for amplifying the DNA damage repair
signal, we show that FCdR induced inhibition of HCT116 cells at G2/M is mediated through activation of DNA
damage response pathway.
Keywords: FCdR, DNA methylation, DNA damage response, Cell cycle, p53, CancerBackground
DNA methylation is a covalent modification of methyl
group on the 5C site of cytosine nucleoside (Robertson
2005; Ren et al. 2011) and is dynamically regulated by
methylation and demethylation (Carey et al. 2011). High
level of DNA methylation on gene promoters is asso-
ciated with transcriptional repression of genes. During
carcinogenesis, global levels of DNA methylation de-
crease along with progression of cancer. Concomitantly,
promoters of tumor suppressors gain DNA methylation,
which allow cancer cells to grow unrestrained (Robertson
2005; Esteller 2008; Ellis et al. 2009). These observations
have led to the development of small molecule inhibitors
capable of inhibiting DNA methylation. These are thought
to suppress tumorigenesis by activating the expression of
tumor suppressor genes. Some of these DNA methylation
inhibitors, such as Vidaza (5-azacytidine, 5-azaC) and* Correspondence: lilianyun@whu.edu.cn; wumin@whu.edu.cn
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in any medium, provided the original work is pDecitabine (5-aza-20-deoxycytidine, 5-azaCdR) have been
approved by FDA for treatment of myelodysplatic
syndrome (Ellis et al. 2009; Ren et al. 2011). Although
many other non-nucleoside DNA methylation inhibi-
tors have been synthesized, their activities in inhibit-
ing DNA methylation and gene activation are
relatively weaker and their potential use in clinics still
needs to be investigated (Chuang et al. 2005). 5-
fluoro-20-deoxycytidine (FCdR, FdCyd) is a well-
known DNA methylation inhibitor discovered in early
1990’s and is currently under evaluation in clinical
trials of breast cancer and other advanced solid
tumors (Gowher and Jeltsch 2004; Ellis et al. 2009;
Ren et al. 2011).
Like Vidaza and Decitabine, FCdR is a pyrimidine
analogue and can integrate into chromatin, and inhibit
DNA methylation (Ellis et al. 2009). Fluorine occupies
the 5C site of cytidine, which prevents the modification
by methyl group (Ren et al. 2011). Additionally, it was
demonstrated that FCdR is capable of binding andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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further DNA methylation (Jones and Taylor 1980;
Reither et al. 2003). FCdR was found to be not stable in
multiple clinical studies (Beumer et al. 2006), but when
combined with other drugs, such as tetrahydrouridine
(THU) and dihydro-5-azacytidine (DHAC), FCdR showed
increased stability and improved activity (Beumer et al.
2008; Kratzke et al. 2008). However, the molecular mech-
anism of repression of tumor suppression by FCdR has
not been studied in any detail.
Upon treatment with DNA methylation inhibitors,
tumor suppressor genes are activated, which then lead
to cell cycle arrest or apoptosis. p53 is one of the best
characterized tumor suppressor gene, mutated in up to
50% of cancers (Royds and Iacopetta 2006). p53 can be
activated by various signals, such as irradiation or chem-
ical induced DNA damage, abnormal oncogene expres-
sion, microtubule inhibitors and other stress conditions
(Royds and Iacopetta 2006; Kruse and Gu 2009). Upon
activation, p53 is phosphorylated and dissociated from
MDM2, which results in its stabilization (Wade et al.
2010). Activated p53 transcribes a number of genes to
induce cell cycle arrest, apoptosis, and senescence, all of
which help in suppressing tumorigenesis (Vousden and
Prives 2009; Speidel 2010; Aylon and Oren 2011).
Activation of DNA damage response is one of the
most important mechanisms that represses tumorigen-
esis (Lord and Ashworth 2012). Malignancy of tumor is
frequently associated with damage to chromatin, recom-
bination and translocation (Schar 2001). Upon DNA
damage, H2AX is phosphorylated by ATM, ATR or
DNAPK at the DNA repair sites (Bonner et al. 2008).
Phosphorylated H2AX further recruits the above kinases
to the damaged foci, which results in amplification of
the DNA damage signal (Bonner et al. 2008). ATM and
ATR then phosphorylate CHK1, CHK2 and other mole-
cules involved in DNA damage response to arrest cell
cycle (Kastan and Lim 2000; Cimprich and Cortez 2008).
In order to investigate the molecular mechanisms of
tumor repression by FCdR, we studied its effect on cell
fate, gene expression and activation of signaling path-
ways. We found that FCdR represses proliferation of
HCT116 at IC50 between 0.025-0.05 μM. FCdR induced
cell cycle arrest at G2/M phase and activated both p53
signaling and DNA damage response pathways. Our
results suggest that FCdR induced G2/M arrest and sup-
pression of cancer cell proliferation is mediated through
FCdR’s role in activation of DNA repair pathway.
Results and discussion
FCdR inhibits proliferation of multiple cancer cell lines
FCdR is in phase II clinical trial for treatment of breast
cancer and many solid tumors. In order to test if cancer
cells other than breast cancer cells are sensitive to FCdR,we chose HCT116, HEPG2, U2OS and KYSE150 cell
lines representing colorectal carcinoma, hepatocellular
carcinoma, osteosarcoma and oesophageal squamous
cell carcinoma, respectively. We treated these cells with
a series of FCdR concentrations. Surviving cells after
72 h treatment were then used to assay by MTT assay.
FCdR inhibited the proliferation of all the above cell
lines, but to different degrees. HCT116 cells showed less
than 10% survival rate with 1 μM FCdR and IC50 was
between 0.025-0.05 μM (Figure 1A). At the same 1 μM
FCdR concentration, the survival rates of HEPG2, U2OS
and KYSE150 cells were about 40%, 80% and 30%,
respectively. The observations suggest that colorectal
tumors might be more sensitive to FCdR, compared to
hepatocellular carcinoma, osteosarcoma and oesophageal
squamous cell carcinoma.
HCT116 cells are more sensitive to FCdR than SAHA
and 5-azaC
Several small molecules inhibiting epigenetic processes
have been developed with an ability to inhibit cancer
cells. SAHA and 5-azaC are two such small molecule
inhibitors that have been approved by FDA. We tested
and compared the cyto-toxicity of FCdR with SAHA and
5-azaC on HCT116 cells, as well as one novel identified
H3K9 methylation inhibitor BIX01294. We found that
all the drugs tested repressed the proliferation of
HCT116, however, their IC50 differed considerably
(Figure 1B). IC50 of FCdR was lowest between 0.025-
0.05 μM, whereas for 5-azaC, BIX01294 and SAHA, it
was 5 μM, 1.5 μM and 0.25 μM respectively. These find-
ings suggested that HCT116 is much more sensitive to
FCdR compared to SAHA and 5-azaC, which may prove
to be of value in a clinical study.
FCdR induces G2/M arrest in HCT116 cell
Next we sought to study the effect of FCdR on cell cycle
in HCT116 cells. Since drugs targeting DNA methyla-
tion are known to induce cell cycle arrest or apoptosis,
we first performed cell cycle analysis by PI (Propidium
Iodide) staining and analyzed cells with flow cytometry.
Cells treated with 0.05 μM FCdR for 48 h showed upto
24% of cells in G2/M phase (Figure 2A), whereas treat-
ment with 0.5 μM FCdR increased the percentage of
cells in the G2M phase to 75% (Figure 2A). These results
suggest that FCdR induces G2/M arrest in HCT116. To
further substantiate our conclusion, we analysed the ex-
pression of cyclins by western blot (Figure 2B). Treat-
ment with 0.5 μM FCdR for 48 h, resulted in significant
increase in the total levels of cyclin B1.
Persistent cell cycle arrest leads to induction of apop-
tosis. However, HCT116 cells treated with FCdR at con-
centrations of up to 0.5 μM for 48 h, did not show any































































































































































































Figure 1 HCT116 cells are sensitive to FCdR treatment. A. HCT116, HepG2, U2OS and KYSE150 cell lines were treated with FCdR at indicated
concentrations for 72 h and MTT assays performed. HCT116 cells were the most sensitive to FCdR. B. Four inhibitors against epigenetic enzymes
were used to treat HCT116 cells for 72 h, and MTT assay performed to test their toxicity. HCT116 cells were more sensitive to FCdR and SAHA,
compared to 5-azaC and BIX01294. (* p value < 0.05; ** p value < 0.01).
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these cells also did not show any obvious sub-G1 peak,
which is a characteristic of apoptotic cells (Figure 2A).
We further examined the formation of cleaved CASP3
and cleaved PARP, which are hallmarks of apoptosis.
We did not detect any cleaved CASP3 or cleaved
PARP by western blot whereas 5FU treatment, which
induces apoptosis in HCT116 cells, resulted in cleav-
age of CASP3 and PARP (Figure 2C). These observa-
tions suggested that at the given concentration FCdR
solely induces G2/M arrest in HCT116 and not
apoptosis.FCdR alters gene expression pattern by elevating
transcription level
DNA methylation at gene promoters represses tran-
scriptional activation and its inhibitors up regulate ex-
pression of genes. To investigate the mechanism/s
involved in FCdR-induced G2/M arrest, we performed
genome wide RNA sequencing (RNA-seq) of HCT116
cells treated with or without FCdR for 24 h and ana-
lyzed the alterations in gene expression. We also per-
formed a similar experiment with 5-Fluorouracil, a
widely used chemotherapeutic drug which induces
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Figure 2 FCdR arrested HCT116 cells at G2/M phase. A. HCT116 cells were treated with 0.05 μM or 0.5 μM FCdR for 48 h and cell cycle was
analyzed by flow cytometry. Compared with control, percentage of cells at G2/M phase increased significantly after FCdR treatment. B. HCT116
cells were treated with indicated amount of FCdR for 48 h and the cyclins checked by western blot. CyclinB1, which accumulates at G2/M phase,
significantly increased after FCdR treatment. C. HCT116 p53+/+ and p53−/− cells were treated with 0.5 μM FCdR or 375 μM 5-Fu for 48 h and
apoptosis assayed by PARP and CASP3 western blot. 5-Fu treatment caused cleavage of PARP and CASP3, but not FCdR.
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duce background signals we only considered genes,
expressions of which were changed by at least two
fold. We found that FCdR treatment lead to alteration
in expression of a total of 1165 genes, out of which
757 were up regulated and 408 were down regulated
(Figure 3A and Additional file 1: Table S1). A higher
number of up-regulated genes in FCdR treated cells is
expected as FCdR is known to inhibit DNA methyla-
tion. In comparison, 5-Fu treatment resulted in
change in expression of 3296 genes out of which, 2/3
were down regulated (Figure 3A and Additional file 2:
Table S2).Next we looked at alterations of signaling pathways,
and found many of them to be altered in cells treated
with FCdR (Table 1). The pathways, which were signifi-
cantly altered were also related with cancer, including
p53 signaling, DNA repair, DNA replication, cell cycle
(Table 1). We validated the altered expression of 45
genes involved in these pathways by reverse transcrip-
tion followed by quantitative PCR (Figure 3C). We
found that more than 90% of these genes were similarly
altered as in our high throughput sequencing dataset.
We performed cluster analysis of differentially
expressed genes involved in pathways, which were



























































































































































































** * * * * * * * * * * * * *
Figure 3 FCdR induced alteration of global gene expression pattern. 0.5 μM FCdR or 375 μM 5-Fu were used to treat HCT116 cells for 24 h.
Total RNA was used for gene expression pattern analysis by high throughput sequencing. A. The number of differentially expressed genes was
calculated. FCdR caused changes in expression of 1165 genes, out of which 757 were up-regulated and 408 were down-regulated. 5-Fu caused
changes in expression of 3295 genes, out of which 1103 were up-regulated, and 2193 were down-regulated. FCdR-treated cells have a much
higher percentage of up-regulated genes. B. Differentially expressed genes involved in top 6 pathways (p53 signaling pathway, colorectal cancer,
nucleotide excision repair, DNA replication, cell cycle, pathways in cancer) were subjected to cluster analysis. C. The change in expression of
45 genes was confirmed by real time PCR. (* p value < 0.05; ** p value < 0.01).
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cation, cell cycle, pathways in cancer. We observed that
both FCdR and 5-Fu treatment lead to similar changes
in genes involved in DNA replication, DNA damage re-
pair and p53 pathway (Figure 3B). Expression of a num-
ber of genes involved in DNA replication and repair
were reduced in cells with both drugs. p53 target genes
such as MDM2, CDKN1A/p21, SFN/14-3-3σ, and SER-
PINE1/PAI were also found to be activated in both sam-
ples, though in comparison to FCdR, 5-Fu treatment
resulted in stronger up-regulation of these p53 targets
(Figures 3B and 4A). Among the genes up-regulated by
FCdR, we also found several well-known proto-onco-
genes, such as HRAS, CMYC and ERBB2 (Figure 3B
and C). Increased expression of these genes might haveimplications in cancer treatment. Interestingly, we also
observed that the receptor of TRAIL, TRAILR2, and the
two decoy receptors, TRAILR3 and TRAILR4, were
overexpressed (Figure 3C). TRAIL is a potential drug-
able protein which is known to induce apoptosis in
many cancer cell lines but not in normal cells. It will be
interesting to look at the effect of cancer treatment com-
bining FCdR with TRAIL.
FCdR treatment activated p53 signaling pathway
in HCT116
Our gene expression analysis of FCdR treated HCT116
cells suggest that FCdR activates p53 signaling pathway,
which is the most important pathway inhibiting tumori-
genesis. We further tested and confirmed the activation
Table 1 Top 20 pathways altered in FCdR treated cells
# Pathway DEGs with pathway
annotation (594)
All genes with pathway
annotation (9952)
Pvalue Qvalue Pathway ID
1 p53 signaling pathway 16 (2.69%) 67 (0.67%) 1.38E-06 1.56E-04 ko04115
2 Colorectal cancer 14 (2.36%) 62 (0.62%) 1.26E-05 9.54E-04 ko05210
3 Nucleotide excision repair 12 (2.02%) 48 (0.48%) 1.75E-05 9.94E-04 ko03420
4 DNA replication 10 (1.68%) 36 (0.36%) 3.28E-05 1.49E-03 ko03030
5 Cell cycle 20 (3.37%) 128 (1.29%) 6.57E-05 2.49E-03 ko04110
6 Pathways in cancer 36 (6.06%) 323 (3.25%) 2.06E-04 6.00E-03 ko05200
7 Limonene and pinene
degradation
3 (0.51%) 3 (0.03%) 2.12E-04 6.00E-03 ko00903
8 Biosynthesis of secondary
metabolites
26 (4.38%) 225 (2.26%) 8.97E-04 2.26E-02 ko01110
9 Metabolic pathways 92 (15.49%) 1132 (11.37%) 1.07E-03 2.43E-02 ko01100
10 Benzoate degradation 4 (0.67%) 9 (0.09%) 1.24E-03 2.57E-02 ko00362
11 Mismatch repair 6 (1.01%) 23 (0.23%) 1.86E-03 3.26E-02 ko03430
12 Prostate cancer 13 (2.19%) 88 (0.88%) 2.05E-03 3.26E-02 ko05215
13 Cell cycle - yeast 11 (1.85%) 68 (0.68%) 2.13E-03 3.26E-02 ko04111
14 Bladder cancer 8 (1.35%) 40 (0.4%) 2.16E-03 3.26E-02 ko05219
15 Meiosis - yeast 10 (1.68%) 59 (0.59%) 2.35E-03 3.33E-02 ko04113
16 Ribosome 13 (2.19%) 90 (0.9%) 2.52E-03 3.36E-02 ko03010
17 Adherens junction 11 (1.85%) 70 (0.7%) 2.70E-03 3.41E-02 ko04520
18 Base excision repair 7 (1.18%) 34 (0.34%) 3.41E-03 4.04E-02 ko03410
19 Naphthalene degradation 2 (0.34%) 2 (0.02%) 3.56E-03 4.04E-02 ko00626
20 Focal adhesion 22 (3.7%) 199 (2%) 3.76E-03 4.06E-02 ko04510
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p53 target genes. We tested 11 p53 downstream genes
and found that all were significantly elevated in expres-
sion (Figure 4A). As the activation of p53 involves
stabilization of p53 protein, we analysed and found that
the amount of p53 protein significantly increased after
FCdR treatment, combined with the discovery that mul-
tiple p53 target genes increased their expression, sug-
gesting that FCdR probably activates p53 pathway
(Figure 4B).
In order to investigate if p53 signaling pathway is re-
sponsible for cell cycle arrest caused by FCdR treatment,
we performed FCdR treatment in a p53 kncokout
HCT116 cell line. We first verified the absence of p53
protein in these cells by western blot (Figure 4C). These
cells, when treated with FCdR at a concentration of
0.5 μM, did not activate p53 target genes, including
GADD45A, GADD45B and 14-3-3σ (Figure 4D). To our
surprise, FCdR was still able to induce G2/M arrest in
these cells in the absence of p53 (Figure 4E). Compared
with parental HCT116 cells (Figure 2A), these cells
showed G2/M arrest and similar distribution profile of
other phases of cell cycle Also, cyclin B1 accumulation
was comparable to parental cells (Figure 5A). Taken to-
gether, above observations suggest that the G2M arrestobserved in FCdR treated cells is not a consequence of
activation of the p53 pathway.FCdR induces DNA damage response in HCT116
Since FCdR is capable of integrating into chromatin, and
our FCdR treatment of HCT116 cells activated tran-
scription of genes involved in DNA repair (Table 1), we
investigated if FCdR has a role in DNA damage response
pathway. To assess it, we first performed alkaline comet
assay, and found that HCT116 cells treated with a low
concentration of 0.02 μM FCdR for 12 h exhibited DNA
damage similar with 100 μM 5-Fu, and the extent of
DNA breaks increases at increasing doses of FCdR
(Figure 5A and B). We then tested for phosphorylation
of H2AX, ATM and CHK1, which are hallmarks of acti-
vated DNA repair pathway, and occur early during the
DNA repair response. Western blot results showed a
dramatic increase in levels of phosphorylated H2AX,
ATM and CHK1 in HCT116 cells treated with 0.5 μM
FCdR (Figure 5C). Immunofluorescent staining also
showed accumulation of phosphorylated H2AX in the
nuclei of FCdR treated HCT116 cells (Figure 5D). Since
it is well known that activation of DNA damage re-
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Figure 4 FCdR treatment activates p53 pathway. A. Differentially expressed genes of p53 signaling pathway found in high throughput RNA
sequencing were confirmed by real time PCR. B. HCT116 wild type cells were treated with indicated amounts of FCdR for 24 h and p53 was
analyzed by western blot. C. HCT116 p53+/+ and p53−/− cells were verified by western blot. D. p53−/− cells were treated with 0.5 μM FCdR for
24 h and expression of indicated p53 downstream genes assayed by real time PCR. These genes were not activated with p53 deficiency.
E. p53−/− cells were treated with FCdR for 48 h and cell cycle was analyzed. FCdR was still able to induce G2/M arrest without p53.
(* p value < 0.05; ** p value < 0.01).
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of FCdR-induced cell cycle arrest.
To test if the induction of DNA damage response is a
common feature for DNA methylation inhibitors, wetreated HCT116 cells with various drugs, including two
inhibitors of DNA methylation, FCdR and 5-azaC, and a
histone deacetylase inhibitor SAHA. We observed that
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Figure 5 (See legend on next page.)
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Figure 5 DNA damage response is responsible for FCdR-induced cell cycle arrest. A. Cells were treated with indicated amount of chemicals
for 12 h and damaged DNA was detected by alkaline comet assay. B. Olive tail moment in the previous assay was calculated according to
manufacturer’s method and the statistic results were shown. C. HCT116 p53+/+ and p53−/− cells were treated with FCdR. Markers for DNA
damage response (pH2AX, pATM and pCHK1) and cell cycle (Cyclin B1, Cyclin D1 and Cyclin E1) were analyzed by western blot. Histone H3 and
β-ACTIN were used as loading controls. D. HCT116 p53+/+ and p53−/− cells were treated with FCdR for 8 h and immunofluorescence staining was
performed to show FCdR induced H2AX phosphorylation in both cell lines. E. Three drugs were used to treat HCT116 for 8 h and DNA damage
responses were investigated by western blotting. FCdR and 5-azaC were able to induce phosphorylation of H2AX, ATM and CHK1, but not SAHA.
H3 was used as control. F. The inhibitory effect of LY294002 to FCdR induced DNA damage response was assayed. G. Addition of 50 μM
LY294002 restored the G2/M arrest induced by 0.1 μM FCdR. (* p value < 0.05).
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treatment did not show a significant increase
(Figure 5E). This indicated that at least two DNA methy-
lation inhibitors, FCdR and 50azaC, are able to activate
DNA damage pathway at the indicated concentration.
To confirm if DNA damage response is the primary
reason for FCdR induced cell cycle arrest, we investi-
gated if addition of a small molecule LY294002, an in-
hibitor of DNA damage response can suppress the
activation of FCdR mediated DNA damage response
pathway. LY294002 inhibits the activity of multiple PI3K
kinases, including ATM and ATR, the two key kinases
involved in DNA damage response. Various combina-
tions of different concentrations of FCdR and LY294002
were tested.We found that at concentrations higher than
50 μM, LY294002 inhibits phosphorylation of ATM and
CHK1 induced by 0.1 μM FCdR (Figure 5F). We per-
formed cell cycle analysis on cells treated with both
FCdR and LY294002, and compared with cells treated
only with FCdR. We found that G2/M arrest observed in
cells treated with 0.1 μM FCdR was completely abol-
ished in cells treated additionally with DNA damage
response inhibitor LY294002 (Figure 5G). This observa-
tion suggests that FCdR induced G2/M arrest is
mediated through activation of DNA damage response
pathway.
Conclusions
The inhibitors of DNA methylation and histone deacety-
lation have shown similar curative effects and reduced
toxicity, compared to traditional chemotherapy drugs in
treatment of cancers. To speed up their use in cancer
treatment, it is critical to elucidate the cellular response
and molecular mechanisms of these drugs. FCdR is a
promising drug in clinical trial. However, we know little
about the kinds of tumors which are sensitive to FCdR
and the molecular mechanisms of FCdR mediated sup-
pression of tumorigenesis. We found that HCT116, a
colon cancer cell line, was extremely sensitive to FCdR,
which suggested that FCdR might be effective in treat-
ment of certain types of colon cancer. FCdR inhibits
HCT116 proliferation by arresting cell cycle at G2/M
phase, without activating the apoptotic pathway. By glo-
bal gene expression profiling we found that p53signaling is activated upon FCdR treatment. Interest-
ingly, FCdR induced cell cycle arrest was not dependent
on the activation of p53 pathway. Many chemotherapy
drugs induce death in cancer cells through p53 activa-
tion; however, since p53 is mutated in more than 50%
cancers, the curative effects of chemotherapy drugs vary
among patients. FCdR might be useful in treating
tumors with mutation in p53 gene.
Our results show that FCdR treatment causes global
changes in gene expression in HCT116 cells, which may
help us better understand the molecular mechanisms of
FCdR-induced cellular responses. Not only had we
observed up regulation of tumor suppressor genes, such
as p21 and PUMA, we also observed increase of HRAS
and CMYC, two well known oncogene. It will be import-
ant to evaluate their roles in FCdR-induced response.
Compared with 5-Fu, FCdR caused less genes to express
differentially but a higher percentage of upregulated
genes. The ability of FCdR to inhibit DNA methylation
may explain the observation that most altered genes
were upregulated in FCdR treated cells.
FCdR also activated DNA damage response pathway,
possibly due to its ability to incorporate into chromatin.
Since, an inhibitor of ATM/ATR kinases, LY294002, can
rescue the cell cycle arrest induced by FCdR, it sug-
gested the activation of ATM/ATR pathways is respon-
sible for the observed cell cycle arrest. It is likely that
FCdR inhibits cell growth primarily by activating the
DNA damage response pathway. The activation of p53 is
an important consequence of DNA damage response.
FCdR induced cell cycle arrest is not dependent on p53
activation, which suggests other molecules downstream
of DNA damage pathway might be responsible. Another
inhibitor of DNA methylation, 5-azaC also induced
DNA damage response, but not SAHA, an inhibitor of
histone deacetylation. It will be interesting to investigate
if DNA damage response is a common mechanism
involved in growth inhibition caused by DNA methyla-
tion inhibitors.
Materials and methods
Cell lines, antibodies and reagents
FCdR, 5-azaC, 5-azaCdR and BIX01294 were purchased
from Sigma. SAHA (Vorinostat) was purchased from
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ATCC. KYSE150 was purchased from Cell Bank of
Chinese Academy of Medical Science. HepG2 was a
gift from Dr. Jianguo Wu (Wuhan University). HCT116
p53−/− cell was a gift from Dr. Pengfei Wang of Stowers
Institute for Medical Research. The antibodies against
Cyclin B1 (Epitomics), Cyclin D1 (Epitomics), Cyclin E1
(Epitomics), p-H2AX (Epitomics), p-ATM (Epitomics),
p-CHK1 (Epitomics), β-ACTIN (CWBIO), CASP
(Cell Signaling) and H3 (Abcam), were purchased from
indicated companies. Rabbit anti-PARP was a gift from
Dr. Xiaodong Zhang (Wuhan University). Rabbit anti-
p53 was raised in our lab against purified full length pro-
tein. The PCR primers are given in Additional file 3:
Table S3.MTT assay
Cells were split at 1×103 cells per well in 96-well plate.
After 24 h cells were treated with drugs and cultured for
72 h. 25 μg MTT was then added to each well and cells
incubated for 4 h at 37°C. The medium with the forma-
zan sediment was dissolved in 50% DMF and 30% SDS
(pH4.7). The absorption was read at 570nM. P value was
calculated by t test.Cell cycle assay
Cells were split at 2-3×105cells per well in 6-well plates.
After 12-14 h cells were treated with drugs and cultured
for 48 h. Cells were harvested by 0.05% Trypsin-EDTA
digestion and centrifuged after PBS wash. Cells were
fixed overnight with 70% ethanol. Flow cytometry ana-
lysis was performed after PI staining (50ug/mL) and
RNase digestion (100ug/mL) at 37°C for 30 min.Western blot
Approximately 2 × 106 Cells were lyzed in 200ul 1×SDS
loading buffer () and boiled at 95°C for 10 min. 5-10 μl
sample was loaded to SDS PAGE gel for each lane and
the separated proteins were transferred to nitrocellular
membrane. The membrane was blocked in 5% milk and
hybridized with indicated first antibody over night and
second antibody for 1 h before developing.Immuno-fluorescence staining
Cells were cultured on cover slips, washed twice with
PBS and then fixed with chilled methanol. Cells were
then washed three times with PBS and blocked in PBS
with 1% BSA for 10 min. Cells were incubated with pri-
mary and secondary antibodies for one hour, respect-
ively. Samples were mounted with prolong anti-fade kit
(Invitrogen) and observed on a fluorescent microscope.Reverse transcription and quantitative PCR
Cells were scraped and collected by centrifugation. Total
RNA was extracted with RNA extraction kit (Yuanpinghao)
according to manufacturer’s protocol. Approximately 1ug
of total RNA was used for reverse transcription with a first
strand cDNA synthesis kit (Toyobo). The amount of
mRNA was assayed by quantitative PCR. β-actin was used
to normalize the amount of each sample. Assays were
repeated at least three times. Data shown were average
values ± SD of one representative experiment. P value was
calculated by t test.
Alkaline comet assay
OxiSelect Comet assay kit was purchased from Cell Bio-
labs and comet assay was performed according to the
manufacturer’s protocol. Briefly, cells were split at 2-
3×105 cells per well in 6-well plate and cultured for
12 h. Drugs were added to the medium and cells were
treated for indicated time. Individual cells are mixed
with molten agarose and then treated with lysis buffer
and alkaline solution. Following electrophoresis, the
samples were dried and stained with a DNA dye, then
observed with fluorescent microscope. The tail length of
each cell was measured manually and the tail DNA per-
centage was quantified by using Quantity One software
(Bio-rad). Then the Olive tail moment was calculated
according to the following formula: Tail DNA% X Tail
moment length, as suggested by provided manual. Data
shown were average values ± SD. P value was calculated
by t test.
Next generation sequencing and data analysis
The cells were treated with desired drugs for 24 h before
collection. Total RNA was extracted and reverse tran-
scribed. Then the cDNA were analyzed by BGI. To study
the relationship of the differential expressed genes, the
values of selected genes were submitted for cluster ana-
lysis by using Cluster3.0 and the heatmap was presented
by Java Treeview.
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